A commentary on the development of engineered phage as therapeutics
- PMID: 34237459
- DOI: 10.1016/j.drudis.2021.06.013
A commentary on the development of engineered phage as therapeutics
Abstract
The use of engineered phages offers a unique opportunity to improve on wild-type (WT) phages to generate ever more successful therapeutics to combat bacterial infections. Here, we discuss how phage engineering could be used to overcome some of the technical challenges of phage therapy, and suggest some areas in which more research will be crucial to the development of further novel phage therapeutics.
Keywords: Bacteriophage therapy; Engineered bacteriophages; Genetically modified organisms; PK/PD; Phage cocktails; Regulatory approval; Spectrum of activity; Stability; Wild type bacteriophages.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interests A.M.L.B. is Molecular Biology Manager at Phico Therapeutics Ltd. and an inventor on European patent EP3201323. H.I.M.F. is Founder and CEO of Phico Therapeutics Ltd. and an inventor on European patents EP3201323 and EP3340200.